# Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

> **NCT01945294** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 257 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Boceprevir
- **BIOLOGICAL:** Peg-interferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01945294
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-10
- **Primary completion:** 2015-08-05
- **Final completion:** 2015-11-04
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945294, "Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01945294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*